http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 28 Jul 2026 16:13:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Entera+Bio+Ltd.+++++++++++For%3A+Jul+26/26827231.html si-local-file:///var/storage/secattach/20260728/26827231.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Entera+Bio+Ltd.+++++++++++For%3A+Jul+26/26827231.html Tue, 28 Jul 2026 16:13:00 -0400 ENTX O.38505617 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Entera+Bio+Ltd.+++++++++++For%3A+Jul+26/26827231.html si-local-file:///var/storage/secattach/20260728/26827231.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Entera+Bio+Ltd.+++++++++++For%3A+Jul+26/26827231.html Tue, 28 Jul 2026 16:13:00 -0400 ENTX O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275M+private+placement+led+by+BVF+Partners/26816623.html Mon, 27 Jul 2026 08:30:33 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275+million+private+placement+led+by+BVF+Partners/26816618.html <p>Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a press release issued July 27, 2026.</p> <p>The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management, among others.</p> <p>Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded http://www.streetinsider.com/Equity+Offerings/Entera+Bio+prices+%24275+million+private+placement+led+by+BVF+Partners/26816618.html Mon, 27 Jul 2026 08:30:26 -0400 ENTX http://www.streetinsider.com/Press+Releases/Entera+Bio+Announces+Pricing+of+Oversubscribed+%24275+Million+Private+Placement+/26816577.html <p align="center"><i>The offering is led by existing investor BVF Partners L.P.</i></p> <p align="center"><i>Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis</i></p> <p align="justify">TEL AVIV, July 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement (the "Purchase Agreement") for an oversubscribed private placement financing (the "Private http://www.streetinsider.com/Press+Releases/Entera+Bio+Announces+Pricing+of+Oversubscribed+%24275+Million+Private+Placement+/26816577.html Mon, 27 Jul 2026 08:30:00 -0400 ENTX http://www.streetinsider.com/Globe+Newswire/Entera+Bio+Announces+Pricing+of+Oversubscribed+%24275+Million+Private+Placement+/26816577.html <p align="center"><i>The offering is led by existing investor BVF Partners L.P.</i></p> <p align="center"><i>Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis</i></p> <p align="justify">TEL AVIV, July 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement (the "Purchase Agreement") for an oversubscribed private placement financing (the "Private http://www.streetinsider.com/Globe+Newswire/Entera+Bio+Announces+Pricing+of+Oversubscribed+%24275+Million+Private+Placement+/26816577.html Mon, 27 Jul 2026 08:30:00 -0400 ENTX http://www.streetinsider.com/Press+Releases/Entera+Bio+Announces+Pricing+of+Oversubscribed+%24275+Million+Private+Placement/26816613.html <p align="center"><i>The offering is led by existing investor BVF Partners L.P.</i></p> <p align="center"><i>Expected gross proceeds are anticipated to extend the Company&apos;s cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis</i></p> <p align="justify">TEL AVIV, July 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement (the &quot;Purchase Agreement&quot;) for an oversubscribed private placement financing (the &quot;Private http://www.streetinsider.com/Press+Releases/Entera+Bio+Announces+Pricing+of+Oversubscribed+%24275+Million+Private+Placement/26816613.html Mon, 27 Jul 2026 08:30:00 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617 http://www.streetinsider.com/Press+Releases/Entera+Bio+Announces+Pricing+of+Oversubscribed+%24275+Million+Private+Placement/26816613.html <p align="center"><i>The offering is led by existing investor BVF Partners L.P.</i></p> <p align="center"><i>Expected gross proceeds are anticipated to extend the Company&apos;s cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis</i></p> <p align="justify">TEL AVIV, July 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement (the &quot;Purchase Agreement&quot;) for an oversubscribed private placement financing (the &quot;Private http://www.streetinsider.com/Press+Releases/Entera+Bio+Announces+Pricing+of+Oversubscribed+%24275+Million+Private+Placement/26816613.html Mon, 27 Jul 2026 08:30:00 -0400 A.06822034 A.06891908 A.11321678 A.14185667 A.31082583 A.36817542 A.50213959 A.50214655 ENTX O.00184548 O.02836754 O.10869727 O.13812452 O.20026344 O.21786748 O.22066148 O.25213119 O.38505617